EVERSANA’s deep bench of oncology experts leverage their extensive industry experience to inform strategies and deliver services that pave the way to commercial success. In an effort to share expert knowledge and help manufacturers understand the complexities of commercialization for new oncology therapies, EVERSANA developed a robust library of resources.
Watch recordings from industry-leading conferences, download white papers and review recent media publications.
Jonathan Kish, General Manager, Real Word Evidence, is a versed expert in Data and Analytics and oncology. He recently demonstrated the value of Real World Evidence in understanding cancer patients’ journeys in his latest abstracts published in the ASCO Journal.
NAVLIN Insights delivers the most innovative market research solutions for oncology manufacturers, from pipeline to loss of exclusivity. Our proprietary insights, which are derived from an unrivaled expert panel network, are combined with an advanced set of methods, frameworks and novel solutions to provide competitive intelligence, insights and strategic recommendations to support the best possible access for your therapy.
Monitor key trends in commercial and government markets to understand how payers are managing access to oncolytics relative to other therapeutic areas.
Assess the current and future access environment within a specific cancer type, supporting brand strategies for in-line brands and pipeline assets.
Benchmark company performance against competitors of competencies and attributes that promote stronger relationships with cancer centers and oncology group practices.
Provide insights on enrollment trends and business strategies of leading cancer centers to support development of effective business and account plans.
Benchmark oncology patient services programs on levels of user importance/value, use, and satisfaction to identify operating gaps and highlight industry best practices, allowing companies to improve patient access to therapy.
Tap into our panel of payer and leading oncology group executives, as well as practicing oncologists to answer your specific business questions.
Payers balance the severity of disease with the need to control high-dollar utilization. As pharmacy spend continues to rise, payers are seeking ways to manage costs in the highest cost therapeutic areas, including oncology. While there is appetite to manage access for both oral and office-administered oncology agents, payers struggle with which tactics to implement without sacrificing patient […]
“Solving the Wastage Challenge Through Predictive Analytics and Modeling,” authored by John Chatas, Principal, Specialty Consulting, EVERSANA and Lee Ann Steadman, Senior Vice President, Specialty Consulting, EVERSANA explores how legislative changes like the Wastage Reduction Act are driving pharma companies to find innovative ways to minimize product wastage & avoid costly fines. EVERSANA’s #SpecialtyConsulting supports […]
Disease awareness is an essential component to successful commercialization, and our award-winning agency, EVERSANA INTOUCH, has mastered the communication complexity of oncology. Learn why they are the trusted partner for oncology manufacturers.
Awareness about ovarian cancer was lacking. We changed that in a big way.
Learn More
Real, personal stories make connections to empower patients and caregivers.
Learn More
Capturing brilliance, sense of hope, energy and strength from a community.
Learn MoreTelehealth can’t be underestimated as a new model to improve patient care.
Learn More
Launching the world's first digital platform designed for Black women by Black women.
Learn More
Removing barriers to quality care with a smart and compelling campaign.
Learn More
The line that slashes through the equal sign is the ugliest blemish on all healthcare, symbolizing the many racial and gender disparities that impact African American women.
Learn More
mart oncology brands understand that the need to combine three things to succeed: Positioning, Storytelling and Targeting.
Learn More
Oncology marketing efforts must adapt to the changing landscape by mapping Dx and Tx journeys through the unique lens of the tumor itself.
Learn More